HBM Holdings Limited announce that Mr. Weihao Xu ("Mr. Xu") has been appointed as the chief business officer. Mr. Xu will be responsible for leading the overall management of the Company's Finance, Public Relations and Investor Relations Department and overseeing all aspects of the Company's financial operations. He is expected to manage the Group's financial and business activities and develop and maintain relationships with existing and potential investors.

In addition, he will initiate with his roles as the CBO, the Global Head of Business Development and Corporate Development of the Group and be responsible for developing and executing strategy for partnership and corporate investment, building innovation capabilities as well as an overall business ecosystem to drive growth. Mr. Xu has more than 16 years of extensive experience in global capital markets, equity investment and financial management. Before joining the Group, Mr. Xu served as chief finance officer at Alphamab Oncology, CASI Pharmaceuticals, and 111 Inc. Prior to that, he was active in the investment industry, working as the portfolio manager for Matthews Asia and several other international investment institutions, where he was responsible for global equity investments.

Since joining the Company, Mr. Xu had led several collaboration projects which validated the Company's global vision and strategy, including the global out -license agreement of HBM7022 with AstraZeneca, out-license agreement of HBM9161 with CSPC and out-license and collaboration agreement with Moderna. Mr. Xu holds a master's degree in Accounting and Financing from Columbia Business School. He also completed a certified program in High Impact Cancer Research from Harvard Medical School.

The Board believes that Mr. Xu will make valuable contributions to the Group with his substantial leadership and financial experience.